These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1419 related items for PubMed ID: 26729443

  • 1. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM.
    J Clin Oncol; 2016 Mar 01; 34(7):721-30. PubMed ID: 26729443
    [Abstract] [Full Text] [Related]

  • 2. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
    Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, Mansukhani M, Koul S, Halmos B, Borczuk AC.
    J Clin Oncol; 2016 Mar 10; 34(8):794-802. PubMed ID: 26215952
    [Abstract] [Full Text] [Related]

  • 3. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM.
    J Thorac Oncol; 2017 Jan 10; 12(1):137-140. PubMed ID: 27666659
    [Abstract] [Full Text] [Related]

  • 4. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
    Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.
    Clin Cancer Res; 2020 Jan 15; 26(2):439-449. PubMed ID: 31548343
    [Abstract] [Full Text] [Related]

  • 5. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
    Caparica R, Yen CT, Coudry R, Ou SI, Varella-Garcia M, Camidge DR, de Castro G.
    J Thorac Oncol; 2017 Jan 15; 12(1):141-144. PubMed ID: 27664533
    [Abstract] [Full Text] [Related]

  • 6. MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.
    Song Z, Wang X, Zheng Y, Su H, Zhang Y.
    Clin Lung Cancer; 2017 Mar 15; 18(2):213-219.e2. PubMed ID: 28322191
    [Abstract] [Full Text] [Related]

  • 7. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ.
    J Thorac Oncol; 2016 Aug 15; 11(8):1242-1245. PubMed ID: 27343442
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.
    Liu SY, Gou LY, Li AN, Lou NN, Gao HF, Su J, Yang JJ, Zhang XC, Shao Y, Dong ZY, Zhou Q, Zhong WZ, Wu YL.
    J Thorac Oncol; 2016 Sep 15; 11(9):1503-10. PubMed ID: 27257131
    [Abstract] [Full Text] [Related]

  • 10. MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
    Heist RS, Shim HS, Gingipally S, Mino-Kenudson M, Le L, Gainor JF, Zheng Z, Aryee M, Xia J, Jia P, Jin H, Zhao Z, Pao W, Engelman JA, Iafrate AJ.
    Oncologist; 2016 Apr 15; 21(4):481-6. PubMed ID: 27022036
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.
    Anticancer Res; 2012 Sep 15; 32(9):3785-90. PubMed ID: 22993320
    [Abstract] [Full Text] [Related]

  • 13. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
    Saigi M, McLeer-Florin A, Pros E, Nadal E, Brambilla E, Sanchez-Cespedes M.
    Clin Transl Oncol; 2018 Jul 15; 20(7):881-888. PubMed ID: 29139039
    [Abstract] [Full Text] [Related]

  • 14. Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.
    Klempner SJ, Borghei A, Hakimian B, Ali SM, Ou SI.
    J Thorac Oncol; 2017 Jan 15; 12(1):152-156. PubMed ID: 27693535
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.
    Castiglione R, Alidousty C, Holz B, Wagener S, Baar T, Heydt C, Binot E, Zupp S, Kron A, Wolf J, Merkelbach-Bruse S, Reinhardt HC, Buettner R, Schultheis AM.
    Mod Pathol; 2019 May 15; 32(5):627-638. PubMed ID: 30459450
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
    Shalata W, Yakobson A, Weissmann S, Oscar E, Iraqi M, Kian W, Peled N, Agbarya A.
    Oncology; 2022 May 15; 100(9):467-474. PubMed ID: 35679833
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.